Literature DB >> 34073720

Pathological Characterization of Tumor Immune Microenvironment (TIME) in Malignant Pleural Mesothelioma.

Francesca Napoli1, Angela Listì2, Vanessa Zambelli1, Gianluca Witel3, Paolo Bironzo1,2, Mauro Papotti1,4, Marco Volante1, Giorgio Scagliotti1,2, Luisella Righi1.   

Abstract

Malignant pleural mesothelioma (MPM) is a rare and highly aggressive disease that arises from pleural mesothelial cells, characterized by a median survival of approximately 13-15 months after diagnosis. The primary cause of this disease is asbestos exposure and the main issues associated with it are late diagnosis and lack of effective therapies. Asbestos-induced cellular damage is associated with the generation of an inflammatory microenvironment that influences and supports tumor growth, possibly in association with patients' genetic predisposition and tumor genomic profile. The chronic inflammatory response to asbestos fibers leads to a unique tumor immune microenvironment (TIME) composed of a heterogeneous mixture of stromal, endothelial, and immune cells, and relative composition and interaction among them is suggested to bear prognostic and therapeutic implications. TIME in MPM is known to be constituted by immunosuppressive cells, such as type 2 tumor-associated macrophages and T regulatory lymphocytes, plus the expression of several immunosuppressive factors, such as tumor-associated PD-L1. Several studies in recent years have contributed to achieve a greater understanding of the pathogenetic mechanisms in tumor development and pathobiology of TIME, that opens the way to new therapeutic strategies. The study of TIME is fundamental in identifying appropriate prognostic and predictive tissue biomarkers. In the present review, we summarize the current knowledge about the pathological characterization of TIME in MPM.

Entities:  

Keywords:  dendritic cells; immunohistochemistry; mesothelioma; tumor microenvironment; tumor-associated macrophages

Year:  2021        PMID: 34073720     DOI: 10.3390/cancers13112564

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  122 in total

1.  Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma.

Authors:  L Strizzi; A Catalano; G Vianale; S Orecchia; A Casalini; G Tassi; R Puntoni; L Mutti; A Procopio
Journal:  J Pathol       Date:  2001-04       Impact factor: 7.996

2.  Expression of vascular endothelial growth factor in diffuse malignant pleural mesothelioma.

Authors:  J E König; E Tolnay; T Wiethege; K M Müller
Journal:  Virchows Arch       Date:  1999-07       Impact factor: 4.064

3.  Regulatory T cells and cytokines in malignant pleural effusions secondary to mesothelioma and carcinoma.

Authors:  Peter DeLong; Richard G Carroll; Adam C Henry; Tomoyuki Tanaka; Sajjad Ahmad; Michael S Leibowitz; Daniel H Sterman; Carl H June; Steven M Albelda; Robert H Vonderheide
Journal:  Cancer Biol Ther       Date:  2005-03-01       Impact factor: 4.742

4.  Prognostic factors of survival in patients with malignant pleural mesothelioma: an analysis of the National Cancer Database.

Authors:  Maaike Van Gerwen; Naomi Alpert; Andrea Wolf; Nisha Ohri; Erik Lewis; Kenneth E Rosenzweig; Raja Flores; Emanuela Taioli
Journal:  Carcinogenesis       Date:  2019-06-10       Impact factor: 4.944

5.  Independent expression of serum vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) in patients with carcinoma and sarcoma.

Authors:  C Linder; S Linder; E Munck-Wikland; H Strander
Journal:  Anticancer Res       Date:  1998 May-Jun       Impact factor: 2.480

Review 6.  Turning foes to friends: targeting cancer-associated fibroblasts.

Authors:  Xueman Chen; Erwei Song
Journal:  Nat Rev Drug Discov       Date:  2019-02       Impact factor: 84.694

7.  Cell and extracellular matrix interaction models in benign mesothelial and malignant pleural mesothelioma cells in 2D and 3D in-vitro.

Authors:  Rajesh M Jagirdar; Eleftherios D Papazoglou; Eleanna Pitaraki; Olympia A Kouliou; Erasmia Rouka; Lydia Giannakou; Stefanos Giannopoulos; Sotirios I Sinis; Chrissi Hatzoglou; Konstantinos I Gourgoulianis; Sotirios G Zarogiannis
Journal:  Clin Exp Pharmacol Physiol       Date:  2020-12-17       Impact factor: 2.557

8.  Combined Analysis of RNA Sequence and Microarray Data Reveals a Competing Endogenous RNA Network as Novel Prognostic Markers in Malignant Pleural Mesothelioma.

Authors:  Weicheng Duan; Kang Wang; Yijie Duan; Xiuyi Chen; Xufeng Chu; Ping Hu; Bo Xiong
Journal:  Front Oncol       Date:  2021-04-23       Impact factor: 6.244

9.  ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma.

Authors:  Isabelle Opitz; Arnaud Scherpereel; Thierry Berghmans; Ioannis Psallidas; Markus Glatzer; David Rigau; Philippe Astoul; Servet Bölükbas; Jeanette Boyd; Johan Coolen; Charlotte De Bondt; Dirk De Ruysscher; Valerie Durieux; Corinne Faivre-Finn; Dean A Fennell; Francoise Galateau-Salle; Laurent Greillier; Mir Ali Hoda; Walter Klepetko; Aude Lacourt; Phil McElnay; Nick A Maskell; Luciano Mutti; Jean-Claude Pairon; Paul Van Schil; Jan P van Meerbeeck; David Waller; Walter Weder; Paul Martin Putora; Giuseppe Cardillo
Journal:  Eur J Cardiothorac Surg       Date:  2020-07-01       Impact factor: 4.191

10.  Inhibition of FGF/FGFR autocrine signaling in mesothelioma with the FGF ligand trap, FP-1039/GSK3052230.

Authors:  Christina Blackwell; Christian Sherk; Maggie Fricko; Gopinath Ganji; Mary Barnette; Bao Hoang; James Tunstead; Tina Skedzielewski; Hasan Alsaid; Beat M Jucker; Elisabeth Minthorn; Rakesh Kumar; M Phillip DeYoung
Journal:  Oncotarget       Date:  2016-06-28
View more
  2 in total

1.  Informative Power Evaluation of Clinical Parameters to Predict Initial Therapeutic Response in Patients with Advanced Pleural Mesothelioma: A Machine Learning Approach.

Authors:  Raffaella Massafra; Annamaria Catino; Pia Maria Soccorsa Perrotti; Pamela Pizzutilo; Annarita Fanizzi; Michele Montrone; Domenico Galetta
Journal:  J Clin Med       Date:  2022-03-16       Impact factor: 4.241

Review 2.  Recent Advances of Immune Checkpoint Inhibition and Potential for (Combined) TIGIT Blockade as a New Strategy for Malignant Pleural Mesothelioma.

Authors:  Sophie Rovers; Annelies Janssens; Jo Raskin; Patrick Pauwels; Jan P van Meerbeeck; Evelien Smits; Elly Marcq
Journal:  Biomedicines       Date:  2022-03-14
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.